Lead Product(s): Ocriplasmin
Therapeutic Area: Ophthalmology
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Oxurion NV
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 13, 2020
The Agreement with Inceptua will allow Oxurion to focus fully on further advancing its promising next-generation therapeutic pipeline of non-VEGF products for the treatment of diabetic eye disease.